Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin

Osteoporosis International

Volumn 25, Issue 6, 2014, Pages 1709-1715

  Redondo Cerezo, E ^a   Casado Caballero, F ^b   Martin Rodriguez, J L ^b   Hernandez Quero, J ^b   Escobar Jimenez, F ^b   Gonzalez Calvin, J L ^b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c Department of Radiology San Cecilio University Hospital ^*  (Spain)

Author keywords

Bone mineral density; Bone turnover; Lumbar spine; Osteoporosis; Viral hepatitis C

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEOXYPYRIDINOLINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 55; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-BINDING PROTEIN-1; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; BLOOD LEVEL; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HEPATITIS C; HUMAN; LEUKOPENIA; LUMBAR SPINE; MALE; MIDDLE AGED; OSTEOLYSIS; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; URINE LEVEL; BLOOD; BONE REMODELING; CASE CONTROL STUDY; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HEPATITIS C, CHRONIC; LUMBAR VERTEBRA; METABOLIC BONE DISEASE; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PROCEDURES; VIROLOGY; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FEMUR NECK; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; RIBAVIRIN; TUMOR NECROSIS FACTOR DECOY RECEPTORS; YOUNG ADULT;

EID: 84901821530     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2663-z     Document Type: Article

References (33)

1. Collier JD, Ninkovic M, Compston J (2002) Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50:i1-i9
2. Leslie WD, Bernstein CN, Leboff MS (2003) American Gastroenterological Association Clinical Practice Committee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125:941-966
3. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D (1998) Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28:695-699
4. Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gómez J (1997) Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148-154
5. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG (2004) Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 89:4325-4330
6. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516-518
7. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD (1989) Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. J Bone Miner Res 4:113-118
8. Van der Pluijm G, Most W, van der Wee-Pals L, de Groot H, Papapoulos S, Löwik C (1991) Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology 129:1596-1604
9. Kull FC Jr (1988) The TNF receptor in TNF-mediated cytotoxicity. Nat Immun Cell Growth Regul 7:254-265
10. Peetre C, Thysell H, Grubb A, Olsson I (1988) A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 41:414-419
11. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329
12. Diez-Ruiz A, Tilz GP, Gutierrez-Gea F, Gil-Extremera B, Murr C, Wachter H, Fuchs D (1995) Neopterin and soluble tumor necrosis factor receptor type I in alcohol-induced cirrhosis. Hepatology 21:976-978
13. González-Calvin JL, Tilz GP, Gallego-Rojo F, Torres-Almendros M, Widner B, Diez-Ruiz A, Rico-Irles J, Fuchs D (2000) Neopterin, soluble receptors for interleukin-2 and tumor necrosis factor in viral cirrhosis. Pteridines 11:43-47
14. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J (2005) Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 11:1843-1847
15. Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bücker A, Mihm U, von Wagner M, Zeuzem S, Sarrazin C (2008) Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 15:790-796
16. Lin JC, Hsieh TY, Wu CC, Chen PJ, Chueh TH, Chang WK, Chu HC (2012) Association between chronic hepatitis C virus infection and bone mineral density. Calcif Tissue Int 91:423-429
17. Solís-Herruzo JA, Castellano G, Fernández I, Muñoz R, Hawkins F (2000) Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 33:812-817
18. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513-1520
20. Hytiroglou P, Thung SN, Gerber MA (1995) Histological classification and quantitation of the severity of chronic hepatitis: keep it simple. Semin Liver Dis 15:414-421
21. Diaz Curiel M, Carrasco de la Peña JL, Honorato Perez J, Perez Cano R, Rapado A, Ruiz Martinez I (1997) Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. Multicentre Research Project on Osteoporosis. Osteoporos Int 7:59-64
22. Who Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Tech Rep Ser 843. World Health Organization, Geneva
23. Parfitt AM (1980) Morphologic basis of bone mineral measurement: transient and steady-state effects of treatment in osteoporosis. Miner Electrolyte Metab 4:273-287
24. El-Maouche D, Mehta SH, Sutcliffe C, Higgins Y, Torbenson MS, Moore RD, Thomas DL, Sulkowski MS, Brown TT (2011) Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol 55:770-776
25. Gur A, Dikici B, Nas K, Bosnak M, Haspolat K, Sarac AJ (2005) Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? BMC Gastroenterol 5:30
26. Wilkison M, Gauss K, Ran Y, Searles S, Taylor D, Meissner N (2012) Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection. Am J Pathol 181:151-162
27. Moreira RO, Balduíno A, Martins HS, Reis JS, Duarte ME, Farias ML, Borojevic R (2004) Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 75:160-168
28. Trombetti A, Giostra E, Mentha G, Negro F, Rizzoli R (2002) Lack of evidence for ribavirin-induced bone loss. Hepatology 36:255-257
29. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R (1993) Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8:881-889
30. Eriksen EF, Brixen K, Charles P (1995) New markers of bone metabolism: clinical use in metabolic bone disease. Eur J Endocrinol 132:251-263
31. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108:1453-1463
32. Bikle DD, Genant HK, Cann C, Recker RR, Halloran BP, Strewler GJ (1985) Bone disease in alcohol abuse. Ann Intern Med 103:42-48
33. Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S (1989) Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 96:213-221